IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

Core Insights - IN8bio, Inc. announced new preclinical data from its γδ T cell engager (γδ-TCE) platform, demonstrating effective cancer-killing activity in leukemia models while minimizing cytokine release [1][2] Group 1: Technology and Innovation - IN8bio's γδ-TCE platform specifically activates γδ T cells, avoiding the excessive inflammatory responses associated with traditional CD3-based T cell engagers [2] - The lead molecules, INB-619 and INB-633, showed potent anti-cancer activity with minimal inflammatory cytokine release in preclinical studies [2][9] - The platform allows for γδ T cell expansion without genetic engineering, offering a scalable approach to immunotherapy [4] Group 2: Clinical Applications and Future Potential - The early results in leukemia models suggest potential applications for the technology in other hard-to-treat cancers and autoimmune diseases [3][5] - IN8bio is expanding its therapeutic pipeline beyond genetically engineered therapies, exploring various disease indications and partnership opportunities [5] Group 3: Key Findings from Preclinical Studies - INB-619 and INB-633 demonstrated strong, dose-related killing of leukemia cells at low concentrations, activating key γδ T cell subsets [9] - Both molecules promoted activation and degranulation of γδ T cells with minimal changes in dangerous cytokines, reducing the risk of cytokine release syndrome [9]